PATENT CLAIM ANALYSIS

Application Number: 15880726
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "142100"]

Abstract:
The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

Claim (Index 23):
The method according to  claim 21 , wherein the pharmaceutically acceptable carriers, excipients or stabilizers consist of 30 mM histidine, pH 6.0, 200 mM sorbitol and 0.02% Tween-80.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 86.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13877585', '15654854', '14904864', '12704396', '12157599']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7046664418682738
- 35 USC 102 Novelty (BERT): 0.5114522182356738
- Combined Prediction Score: 0.6853450195050138
- Mean Citation Score: 230.968688
- Max Citation Score: 254.1106
- Similarity Product: 162.35634687360525

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test